Rami Doukky
Concepts (381)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Perfusion Imaging | 48 | 2023 | 71 | 22.830 |
Why?
| Tomography, Emission-Computed, Single-Photon | 43 | 2023 | 94 | 14.350 |
Why?
| Coronary Artery Disease | 26 | 2023 | 173 | 13.790 |
Why?
| Purines | 21 | 2020 | 33 | 10.270 |
Why?
| Pyrazoles | 22 | 2020 | 53 | 10.140 |
Why?
| Myocardial Ischemia | 14 | 2020 | 64 | 6.990 |
Why?
| Kidney Failure, Chronic | 12 | 2023 | 188 | 6.060 |
Why?
| Exercise Test | 23 | 2020 | 133 | 5.510 |
Why?
| Myocardial Infarction | 14 | 2023 | 194 | 5.320 |
Why?
| Thrombosis | 10 | 2022 | 74 | 4.930 |
Why?
| Kidney Transplantation | 7 | 2023 | 153 | 4.410 |
Why?
| Adenosine A2 Receptor Agonists | 10 | 2019 | 11 | 4.350 |
Why?
| Prognosis | 34 | 2023 | 1011 | 4.040 |
Why?
| Atrial Fibrillation | 13 | 2022 | 234 | 3.900 |
Why?
| Aminophylline | 9 | 2018 | 9 | 3.490 |
Why?
| Heart Failure | 14 | 2022 | 241 | 3.260 |
Why?
| Humans | 132 | 2023 | 32988 | 3.110 |
Why?
| Heart Diseases | 5 | 2021 | 104 | 2.780 |
Why?
| Middle Aged | 61 | 2022 | 11219 | 2.780 |
Why?
| Renal Insufficiency, Chronic | 5 | 2021 | 113 | 2.770 |
Why?
| Risk Assessment | 22 | 2021 | 814 | 2.640 |
Why?
| Male | 74 | 2023 | 17726 | 2.600 |
Why?
| Female | 75 | 2023 | 18423 | 2.510 |
Why?
| Atrial Appendage | 8 | 2022 | 53 | 2.360 |
Why?
| Echocardiography, Transesophageal | 6 | 2019 | 53 | 2.340 |
Why?
| Patient Selection | 7 | 2021 | 261 | 2.310 |
Why?
| Liver Transplantation | 4 | 2021 | 112 | 2.300 |
Why?
| Risk Factors | 34 | 2023 | 2762 | 2.290 |
Why?
| Vasodilator Agents | 9 | 2018 | 35 | 2.130 |
Why?
| Cardiology | 9 | 2020 | 115 | 2.110 |
Why?
| Retrospective Studies | 32 | 2023 | 3835 | 2.100 |
Why?
| Aged | 48 | 2022 | 10542 | 2.050 |
Why?
| Heart | 7 | 2023 | 119 | 2.020 |
Why?
| Stroke Volume | 9 | 2022 | 67 | 2.020 |
Why?
| Electrocardiography | 6 | 2018 | 230 | 1.900 |
Why?
| Predictive Value of Tests | 17 | 2021 | 626 | 1.870 |
Why?
| Coronary Angiography | 8 | 2023 | 115 | 1.800 |
Why?
| Death, Sudden, Cardiac | 4 | 2015 | 33 | 1.780 |
Why?
| Pulmonary Embolism | 5 | 2022 | 58 | 1.710 |
Why?
| Heart Rate | 3 | 2017 | 165 | 1.660 |
Why?
| Echocardiography | 9 | 2023 | 207 | 1.630 |
Why?
| Reproducibility of Results | 15 | 2019 | 893 | 1.590 |
Why?
| Natriuretic Peptide, Brain | 4 | 2021 | 12 | 1.580 |
Why?
| Diagnostic Imaging | 3 | 2021 | 101 | 1.540 |
Why?
| Prospective Studies | 19 | 2020 | 2002 | 1.500 |
Why?
| Mitral Valve | 3 | 2020 | 20 | 1.380 |
Why?
| Percutaneous Coronary Intervention | 4 | 2022 | 31 | 1.380 |
Why?
| Sensitivity and Specificity | 12 | 2018 | 592 | 1.340 |
Why?
| Nuclear Medicine | 5 | 2019 | 11 | 1.300 |
Why?
| Ventricular Dysfunction, Left | 3 | 2022 | 55 | 1.260 |
Why?
| Randomized Controlled Trials as Topic | 12 | 2022 | 377 | 1.250 |
Why?
| Drug-Eluting Stents | 3 | 2022 | 15 | 1.230 |
Why?
| Cardiovascular Diseases | 6 | 2021 | 446 | 1.200 |
Why?
| Unnecessary Procedures | 3 | 2015 | 29 | 1.200 |
Why?
| Coronary Stenosis | 2 | 2018 | 17 | 1.180 |
Why?
| Troponin I | 2 | 2017 | 21 | 1.180 |
Why?
| Heart-Assist Devices | 4 | 2019 | 32 | 1.170 |
Why?
| Transcatheter Aortic Valve Replacement | 6 | 2023 | 33 | 1.170 |
Why?
| Multimodal Imaging | 3 | 2021 | 30 | 1.160 |
Why?
| Heart Valve Prosthesis Implantation | 4 | 2023 | 53 | 1.120 |
Why?
| Ventricular Function, Left | 5 | 2020 | 63 | 1.100 |
Why?
| Ventricular Dysfunction, Right | 3 | 2021 | 16 | 1.100 |
Why?
| Treatment Outcome | 27 | 2023 | 4036 | 1.040 |
Why?
| United States | 17 | 2023 | 2632 | 1.020 |
Why?
| Heart Valve Diseases | 3 | 2020 | 33 | 1.010 |
Why?
| Angina Pectoris | 2 | 2023 | 18 | 1.010 |
Why?
| Diarrhea | 3 | 2012 | 49 | 1.000 |
Why?
| Comorbidity | 9 | 2021 | 563 | 0.990 |
Why?
| Aortic Valve Stenosis | 5 | 2023 | 33 | 0.960 |
Why?
| Heart Ventricles | 3 | 2021 | 225 | 0.960 |
Why?
| Aortic Valve Insufficiency | 2 | 2023 | 11 | 0.940 |
Why?
| Incidence | 9 | 2020 | 840 | 0.940 |
Why?
| Chicago | 10 | 2019 | 957 | 0.910 |
Why?
| Insurance Coverage | 2 | 2020 | 20 | 0.880 |
Why?
| Medicaid | 2 | 2020 | 43 | 0.870 |
Why?
| Platelet Aggregation Inhibitors | 4 | 2022 | 68 | 0.850 |
Why?
| Medicare | 2 | 2019 | 129 | 0.820 |
Why?
| Hematoma | 1 | 2021 | 25 | 0.820 |
Why?
| Calcium | 3 | 2021 | 531 | 0.810 |
Why?
| Cardiomyopathies | 3 | 2020 | 38 | 0.810 |
Why?
| Coronary Vessels | 1 | 2021 | 56 | 0.800 |
Why?
| Follow-Up Studies | 10 | 2019 | 2053 | 0.800 |
Why?
| Image Enhancement | 2 | 2018 | 61 | 0.800 |
Why?
| Double-Blind Method | 7 | 2016 | 546 | 0.800 |
Why?
| Diltiazem | 1 | 2020 | 5 | 0.780 |
Why?
| Atrioventricular Node | 1 | 2020 | 7 | 0.780 |
Why?
| Cohort Studies | 10 | 2020 | 2077 | 0.780 |
Why?
| Antihypertensive Agents | 2 | 2022 | 93 | 0.780 |
Why?
| Survival Rate | 6 | 2017 | 443 | 0.780 |
Why?
| Hyperkalemia | 1 | 2020 | 7 | 0.780 |
Why?
| Bradycardia | 1 | 2020 | 32 | 0.770 |
Why?
| Primary Health Care | 2 | 2013 | 107 | 0.760 |
Why?
| Critical Pathways | 2 | 2017 | 22 | 0.750 |
Why?
| Patient Protection and Affordable Care Act | 1 | 2020 | 26 | 0.750 |
Why?
| Decision Support Systems, Clinical | 1 | 2019 | 12 | 0.740 |
Why?
| Tissue Survival | 1 | 2019 | 3 | 0.740 |
Why?
| Adult | 15 | 2020 | 9848 | 0.740 |
Why?
| Multidetector Computed Tomography | 2 | 2021 | 12 | 0.740 |
Why?
| Severity of Illness Index | 8 | 2020 | 1242 | 0.740 |
Why?
| Acute Coronary Syndrome | 1 | 2019 | 15 | 0.730 |
Why?
| Calcinosis | 1 | 2020 | 53 | 0.730 |
Why?
| Defibrillators, Implantable | 1 | 2020 | 41 | 0.730 |
Why?
| Syncope | 1 | 2019 | 11 | 0.730 |
Why?
| Bundle-Branch Block | 1 | 2019 | 18 | 0.710 |
Why?
| Esophageal and Gastric Varices | 1 | 2019 | 2 | 0.710 |
Why?
| Cardiac Tamponade | 1 | 2018 | 6 | 0.700 |
Why?
| Echocardiography, Doppler | 2 | 2016 | 30 | 0.700 |
Why?
| Decision Support Techniques | 1 | 2019 | 57 | 0.700 |
Why?
| Artificial Intelligence | 1 | 2019 | 26 | 0.690 |
Why?
| Oximetry | 1 | 2018 | 14 | 0.690 |
Why?
| Aged, 80 and over | 13 | 2022 | 5249 | 0.680 |
Why?
| Arrhythmias, Cardiac | 1 | 2020 | 172 | 0.670 |
Why?
| Pericardial Effusion | 1 | 2018 | 6 | 0.670 |
Why?
| Aortic Valve | 5 | 2023 | 44 | 0.660 |
Why?
| Myocardium | 2 | 2019 | 178 | 0.650 |
Why?
| Contrast Media | 1 | 2018 | 148 | 0.650 |
Why?
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2017 | 1 | 0.620 |
Why?
| Cardiac Imaging Techniques | 1 | 2017 | 8 | 0.620 |
Why?
| Radiopharmaceuticals | 4 | 2020 | 57 | 0.620 |
Why?
| Preoperative Care | 2 | 2015 | 148 | 0.610 |
Why?
| Accreditation | 1 | 2016 | 18 | 0.600 |
Why?
| Purinergic P1 Receptor Antagonists | 2 | 2013 | 2 | 0.590 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2016 | 15 | 0.570 |
Why?
| Hemodynamics | 1 | 2016 | 100 | 0.570 |
Why?
| Diet, Sodium-Restricted | 1 | 2016 | 8 | 0.570 |
Why?
| Cardio-Renal Syndrome | 1 | 2015 | 1 | 0.570 |
Why?
| Prevalence | 7 | 2023 | 554 | 0.570 |
Why?
| Hospitalization | 6 | 2021 | 367 | 0.570 |
Why?
| Guideline Adherence | 4 | 2019 | 78 | 0.560 |
Why?
| Sexism | 1 | 2015 | 9 | 0.550 |
Why?
| Insurance Carriers | 1 | 2015 | 3 | 0.550 |
Why?
| Adenosine | 1 | 2015 | 16 | 0.550 |
Why?
| Technetium | 1 | 2015 | 7 | 0.540 |
Why?
| Cardiotonic Agents | 4 | 2018 | 18 | 0.540 |
Why?
| Registries | 4 | 2023 | 226 | 0.540 |
Why?
| Hospital Mortality | 5 | 2021 | 197 | 0.530 |
Why?
| Perfusion | 4 | 2023 | 24 | 0.530 |
Why?
| Social Class | 1 | 2015 | 77 | 0.530 |
Why?
| End Stage Liver Disease | 1 | 2014 | 18 | 0.520 |
Why?
| Physicians' Offices | 2 | 2013 | 5 | 0.520 |
Why?
| Myocardial Revascularization | 4 | 2020 | 25 | 0.520 |
Why?
| Rheumatic Heart Disease | 1 | 2014 | 1 | 0.510 |
Why?
| Hyperemia | 1 | 2014 | 3 | 0.500 |
Why?
| Echocardiography, Stress | 1 | 2014 | 5 | 0.500 |
Why?
| Thrombophilia | 1 | 2014 | 9 | 0.500 |
Why?
| Hyperthyroidism | 1 | 2014 | 18 | 0.500 |
Why?
| Emigrants and Immigrants | 1 | 2014 | 25 | 0.500 |
Why?
| Thromboembolism | 1 | 2014 | 38 | 0.480 |
Why?
| Heart Failure, Systolic | 1 | 2013 | 6 | 0.480 |
Why?
| Cross-Sectional Studies | 8 | 2020 | 1058 | 0.480 |
Why?
| Technetium Tc 99m Sestamibi | 3 | 2019 | 12 | 0.470 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 45 | 0.470 |
Why?
| Women's Health | 1 | 2015 | 247 | 0.470 |
Why?
| Diabetes Complications | 1 | 2013 | 70 | 0.460 |
Why?
| Urban Population | 1 | 2014 | 164 | 0.460 |
Why?
| Kaplan-Meier Estimate | 4 | 2018 | 216 | 0.460 |
Why?
| Renal Dialysis | 3 | 2019 | 132 | 0.460 |
Why?
| Dizziness | 1 | 2012 | 18 | 0.460 |
Why?
| Lung | 1 | 2014 | 179 | 0.460 |
Why?
| Angina, Unstable | 2 | 2002 | 12 | 0.440 |
Why?
| Abdominal Pain | 1 | 2012 | 9 | 0.440 |
Why?
| Physicians | 1 | 2014 | 136 | 0.430 |
Why?
| Algorithms | 3 | 2019 | 428 | 0.430 |
Why?
| Sex Distribution | 3 | 2016 | 92 | 0.420 |
Why?
| Odds Ratio | 4 | 2018 | 321 | 0.420 |
Why?
| Exercise | 1 | 2016 | 494 | 0.400 |
Why?
| Chi-Square Distribution | 3 | 2018 | 177 | 0.400 |
Why?
| Patient Positioning | 1 | 2011 | 39 | 0.400 |
Why?
| Multivariate Analysis | 3 | 2018 | 386 | 0.390 |
Why?
| Periodicals as Topic | 3 | 2020 | 47 | 0.390 |
Why?
| Time Factors | 6 | 2019 | 1873 | 0.390 |
Why?
| Positron-Emission Tomography | 4 | 2019 | 102 | 0.380 |
Why?
| Ambulatory Care | 1 | 2010 | 85 | 0.380 |
Why?
| Utilization Review | 3 | 2020 | 7 | 0.370 |
Why?
| Practice Guidelines as Topic | 5 | 2017 | 388 | 0.360 |
Why?
| Thallium Radioisotopes | 2 | 2019 | 6 | 0.350 |
Why?
| Troponin | 3 | 2021 | 11 | 0.330 |
Why?
| Radionuclide Imaging | 2 | 2020 | 59 | 0.330 |
Why?
| Acute Disease | 3 | 2021 | 258 | 0.320 |
Why?
| Glomerular Filtration Rate | 2 | 2020 | 77 | 0.310 |
Why?
| Risk | 3 | 2020 | 228 | 0.310 |
Why?
| Drug Administration Schedule | 3 | 2018 | 249 | 0.310 |
Why?
| Stroke | 3 | 2022 | 405 | 0.300 |
Why?
| Benchmarking | 2 | 2023 | 42 | 0.290 |
Why?
| Image Processing, Computer-Assisted | 2 | 2019 | 234 | 0.280 |
Why?
| Causality | 2 | 2016 | 60 | 0.280 |
Why?
| Age Distribution | 2 | 2016 | 109 | 0.280 |
Why?
| Feasibility Studies | 5 | 2022 | 282 | 0.280 |
Why?
| Chronic Disease | 3 | 2019 | 554 | 0.270 |
Why?
| Propensity Score | 2 | 2016 | 56 | 0.270 |
Why?
| ROC Curve | 2 | 2016 | 155 | 0.270 |
Why?
| Proportional Hazards Models | 3 | 2018 | 387 | 0.270 |
Why?
| Administration, Intravenous | 2 | 2016 | 35 | 0.270 |
Why?
| Illinois | 3 | 2021 | 267 | 0.270 |
Why?
| Logistic Models | 2 | 2018 | 474 | 0.270 |
Why?
| Point-of-Care Systems | 2 | 2018 | 30 | 0.260 |
Why?
| Patient Compliance | 2 | 2017 | 200 | 0.260 |
Why?
| Syndrome | 2 | 2023 | 101 | 0.250 |
Why?
| Decision Making | 2 | 2017 | 239 | 0.250 |
Why?
| Cause of Death | 2 | 2015 | 83 | 0.240 |
Why?
| Dyspnea | 1 | 2023 | 39 | 0.230 |
Why?
| Placebo Effect | 2 | 2014 | 26 | 0.230 |
Why?
| Hypotension | 1 | 2022 | 30 | 0.230 |
Why?
| Journal Impact Factor | 2 | 2020 | 16 | 0.230 |
Why?
| Pericardium | 2 | 2021 | 30 | 0.230 |
Why?
| Ultrasonography | 2 | 2014 | 215 | 0.220 |
Why?
| Pulmonary Veins | 1 | 2022 | 25 | 0.220 |
Why?
| Anticoagulants | 3 | 2022 | 153 | 0.220 |
Why?
| Pilot Projects | 3 | 2014 | 466 | 0.220 |
Why?
| Coronary Artery Bypass | 1 | 2022 | 74 | 0.210 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 13 | 0.210 |
Why?
| Technetium Tc 99m Pyrophosphate | 1 | 2020 | 1 | 0.200 |
Why?
| Amyloid Neuropathies, Familial | 1 | 2020 | 3 | 0.200 |
Why?
| Patient Discharge | 2 | 2019 | 169 | 0.200 |
Why?
| Ischemia | 1 | 2020 | 35 | 0.190 |
Why?
| Electric Countershock | 1 | 2020 | 30 | 0.190 |
Why?
| Adipose Tissue | 1 | 2021 | 99 | 0.190 |
Why?
| Sample Size | 1 | 2019 | 26 | 0.190 |
Why?
| Mobile Applications | 1 | 2020 | 36 | 0.190 |
Why?
| Ventriculography, First-Pass | 1 | 2019 | 1 | 0.190 |
Why?
| Prospective Payment System | 1 | 2019 | 4 | 0.190 |
Why?
| Sex Characteristics | 1 | 2021 | 139 | 0.190 |
Why?
| Thrombocytopenia | 1 | 2019 | 31 | 0.180 |
Why?
| Inpatients | 2 | 2019 | 163 | 0.180 |
Why?
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 7 | 0.180 |
Why?
| Health Resources | 1 | 2019 | 28 | 0.180 |
Why?
| Mitral Valve Insufficiency | 1 | 2019 | 13 | 0.180 |
Why?
| Publication Bias | 1 | 2019 | 7 | 0.180 |
Why?
| Asymptomatic Diseases | 1 | 2019 | 21 | 0.180 |
Why?
| Electrodes, Implanted | 1 | 2019 | 51 | 0.180 |
Why?
| Writing | 1 | 2019 | 23 | 0.180 |
Why?
| Cardiac Resynchronization Therapy | 1 | 2019 | 24 | 0.180 |
Why?
| Models, Statistical | 1 | 2019 | 145 | 0.180 |
Why?
| Outpatients | 1 | 2019 | 60 | 0.180 |
Why?
| Antidotes | 1 | 2018 | 6 | 0.180 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 78 | 0.180 |
Why?
| Medication Adherence | 2 | 2020 | 94 | 0.180 |
Why?
| Angioplasty, Balloon | 1 | 2019 | 28 | 0.180 |
Why?
| Pericardial Window Techniques | 1 | 2018 | 3 | 0.180 |
Why?
| Sphygmomanometers | 1 | 2018 | 3 | 0.180 |
Why?
| Plethysmography | 1 | 2018 | 5 | 0.180 |
Why?
| Pericardiocentesis | 1 | 2018 | 4 | 0.180 |
Why?
| Vasodilation | 1 | 2018 | 21 | 0.170 |
Why?
| Death | 2 | 2022 | 48 | 0.170 |
Why?
| Coronary Circulation | 1 | 2018 | 49 | 0.170 |
Why?
| Hypertension, Pulmonary | 1 | 2019 | 27 | 0.170 |
Why?
| Angioplasty, Balloon, Coronary | 2 | 2013 | 52 | 0.170 |
Why?
| Guidelines as Topic | 1 | 2019 | 78 | 0.170 |
Why?
| Cardiac Pacing, Artificial | 1 | 2019 | 84 | 0.170 |
Why?
| Heart Atria | 1 | 2019 | 97 | 0.170 |
Why?
| Respiration | 1 | 2018 | 37 | 0.170 |
Why?
| Hypocalcemia | 1 | 2018 | 4 | 0.170 |
Why?
| Hospitals | 1 | 2019 | 159 | 0.170 |
Why?
| Kidney | 1 | 2020 | 219 | 0.170 |
Why?
| Hospice Care | 1 | 2019 | 36 | 0.170 |
Why?
| Hypercalcemia | 1 | 2018 | 12 | 0.170 |
Why?
| Cardiac Surgical Procedures | 1 | 2019 | 104 | 0.170 |
Why?
| Tachycardia | 1 | 2018 | 49 | 0.170 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 235 | 0.170 |
Why?
| Angina, Stable | 1 | 2017 | 2 | 0.160 |
Why?
| Young Adult | 2 | 2016 | 2287 | 0.160 |
Why?
| Potassium | 1 | 2018 | 72 | 0.160 |
Why?
| Chest Pain | 1 | 2017 | 23 | 0.160 |
Why?
| Research Design | 1 | 2019 | 244 | 0.160 |
Why?
| Kidney Function Tests | 1 | 2017 | 28 | 0.160 |
Why?
| Patient Readmission | 1 | 2019 | 134 | 0.160 |
Why?
| Central Venous Pressure | 1 | 2017 | 6 | 0.160 |
Why?
| Physician-Patient Relations | 1 | 2017 | 47 | 0.160 |
Why?
| Arterial Pressure | 1 | 2017 | 16 | 0.150 |
Why?
| Palliative Care | 1 | 2019 | 158 | 0.150 |
Why?
| Veterans | 1 | 2019 | 96 | 0.150 |
Why?
| Internship and Residency | 1 | 2020 | 209 | 0.150 |
Why?
| Patient Safety | 1 | 2017 | 55 | 0.150 |
Why?
| Organophosphorus Compounds | 1 | 2016 | 7 | 0.150 |
Why?
| Organotechnetium Compounds | 1 | 2016 | 10 | 0.150 |
Why?
| Regression Analysis | 2 | 2015 | 326 | 0.150 |
Why?
| Perfusion Imaging | 1 | 2016 | 14 | 0.150 |
Why?
| Radiation Protection | 1 | 2016 | 8 | 0.150 |
Why?
| Area Under Curve | 1 | 2016 | 77 | 0.140 |
Why?
| Disease Management | 1 | 2017 | 138 | 0.140 |
Why?
| Lipoprotein(a) | 1 | 2016 | 10 | 0.140 |
Why?
| Directive Counseling | 1 | 2016 | 15 | 0.140 |
Why?
| Hospitals, High-Volume | 1 | 2015 | 10 | 0.140 |
Why?
| Sympathetic Nervous System | 1 | 2015 | 14 | 0.140 |
Why?
| Dyslipidemias | 1 | 2016 | 28 | 0.140 |
Why?
| Workload | 1 | 2015 | 39 | 0.140 |
Why?
| Single-Blind Method | 1 | 2015 | 130 | 0.140 |
Why?
| Sex Factors | 2 | 2016 | 548 | 0.140 |
Why?
| Pattern Recognition, Automated | 1 | 2015 | 11 | 0.140 |
Why?
| Diagnostic Errors | 1 | 2015 | 48 | 0.140 |
Why?
| Rest | 1 | 2015 | 32 | 0.130 |
Why?
| Health Services Misuse | 1 | 2015 | 3 | 0.130 |
Why?
| Self Care | 1 | 2016 | 105 | 0.130 |
Why?
| Age Factors | 2 | 2018 | 932 | 0.130 |
Why?
| Computer Communication Networks | 1 | 2014 | 5 | 0.130 |
Why?
| Population Groups | 1 | 2014 | 5 | 0.130 |
Why?
| Self Report | 1 | 2016 | 245 | 0.130 |
Why?
| Robotics | 1 | 2014 | 19 | 0.130 |
Why?
| Gastrointestinal Tract | 1 | 2014 | 56 | 0.130 |
Why?
| Remote Consultation | 1 | 2014 | 16 | 0.130 |
Why?
| Cost-Benefit Analysis | 1 | 2015 | 159 | 0.130 |
Why?
| Surgeons | 1 | 2015 | 98 | 0.120 |
Why?
| Dilatation | 1 | 2013 | 13 | 0.120 |
Why?
| Disease-Free Survival | 1 | 2013 | 228 | 0.110 |
Why?
| Infusions, Intravenous | 1 | 2012 | 87 | 0.110 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 34 | 0.110 |
Why?
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 1 | 0.110 |
Why?
| Premedication | 1 | 2012 | 6 | 0.110 |
Why?
| Injections, Intravenous | 1 | 2012 | 60 | 0.110 |
Why?
| Drug Interactions | 1 | 2012 | 70 | 0.110 |
Why?
| Diagnosis, Differential | 1 | 2013 | 462 | 0.110 |
Why?
| Supine Position | 1 | 2011 | 18 | 0.100 |
Why?
| Asthma | 1 | 2014 | 194 | 0.100 |
Why?
| Safety | 1 | 2010 | 55 | 0.100 |
Why?
| Diastole | 1 | 2010 | 35 | 0.090 |
Why?
| Administration, Oral | 2 | 2022 | 158 | 0.090 |
Why?
| Hemorrhage | 2 | 2022 | 95 | 0.090 |
Why?
| Child | 1 | 2014 | 1634 | 0.090 |
Why?
| Internet | 2 | 2020 | 112 | 0.080 |
Why?
| Body Mass Index | 1 | 2011 | 478 | 0.080 |
Why?
| Aging | 1 | 2018 | 1634 | 0.080 |
Why?
| Adolescent | 1 | 2014 | 2687 | 0.080 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2010 | 230 | 0.080 |
Why?
| Equipment Design | 2 | 2019 | 207 | 0.070 |
Why?
| Receptors, Angiotensin | 1 | 2022 | 2 | 0.060 |
Why?
| Neprilysin | 1 | 2022 | 9 | 0.060 |
Why?
| Equipment Failure | 1 | 2023 | 56 | 0.060 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2022 | 11 | 0.060 |
Why?
| Magnetic Resonance Imaging | 2 | 2019 | 1315 | 0.060 |
Why?
| Lasers | 1 | 2022 | 17 | 0.060 |
Why?
| Bayes Theorem | 1 | 2022 | 49 | 0.060 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 32 | 0.060 |
Why?
| Hematologic Agents | 1 | 2002 | 4 | 0.060 |
Why?
| Vitamin K | 1 | 2022 | 11 | 0.060 |
Why?
| Drug Therapy, Combination | 1 | 2022 | 261 | 0.050 |
Why?
| Fibrinolytic Agents | 1 | 2022 | 96 | 0.050 |
Why?
| Peptide Fragments | 1 | 2021 | 118 | 0.050 |
Why?
| Lost to Follow-Up | 1 | 2019 | 2 | 0.050 |
Why?
| Fellowships and Scholarships | 1 | 2020 | 44 | 0.050 |
Why?
| Data Interpretation, Statistical | 1 | 2019 | 99 | 0.050 |
Why?
| Editorial Policies | 1 | 2019 | 7 | 0.050 |
Why?
| Peer Review, Research | 1 | 2019 | 10 | 0.040 |
Why?
| Authorship | 1 | 2019 | 16 | 0.040 |
Why?
| Endpoint Determination | 1 | 2019 | 31 | 0.040 |
Why?
| Quality Control | 1 | 2019 | 52 | 0.040 |
Why?
| Bibliometrics | 1 | 2019 | 23 | 0.040 |
Why?
| Cardiovascular Agents | 1 | 2019 | 33 | 0.040 |
Why?
| Congresses as Topic | 1 | 2019 | 36 | 0.040 |
Why?
| American Heart Association | 1 | 2019 | 39 | 0.040 |
Why?
| Hospital Costs | 1 | 2019 | 74 | 0.040 |
Why?
| Checklist | 1 | 2019 | 43 | 0.040 |
Why?
| Veterans Health | 1 | 2018 | 3 | 0.040 |
Why?
| United States Department of Veterans Affairs | 1 | 2018 | 11 | 0.040 |
Why?
| Protective Factors | 1 | 2018 | 19 | 0.040 |
Why?
| Software | 1 | 2018 | 77 | 0.040 |
Why?
| Intensive Care Units | 1 | 2021 | 339 | 0.040 |
Why?
| Research Report | 1 | 2017 | 11 | 0.040 |
Why?
| Databases, Factual | 1 | 2019 | 393 | 0.040 |
Why?
| Length of Stay | 1 | 2019 | 382 | 0.040 |
Why?
| Pyridones | 1 | 2016 | 18 | 0.040 |
Why?
| Thiazoles | 1 | 2016 | 38 | 0.040 |
Why?
| Pyridines | 1 | 2016 | 47 | 0.040 |
Why?
| Mortality | 1 | 2017 | 96 | 0.040 |
Why?
| Georgia | 1 | 2016 | 16 | 0.040 |
Why?
| Warfarin | 1 | 2016 | 61 | 0.040 |
Why?
| Socioeconomic Factors | 1 | 2017 | 364 | 0.040 |
Why?
| Cholesterol, LDL | 1 | 2016 | 46 | 0.040 |
Why?
| Current Procedural Terminology | 1 | 2015 | 14 | 0.040 |
Why?
| MEDLINE | 1 | 2015 | 7 | 0.030 |
Why?
| Up-Regulation | 1 | 2016 | 225 | 0.030 |
Why?
| Germany | 1 | 2014 | 13 | 0.030 |
Why?
| Learning Curve | 1 | 2014 | 21 | 0.030 |
Why?
| Phantoms, Imaging | 1 | 2014 | 45 | 0.030 |
Why?
| Materials Testing | 1 | 2014 | 143 | 0.030 |
Why?
| Tomography, X-Ray Computed | 1 | 2019 | 899 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2018 | 1485 | 0.030 |
Why?
| Postoperative Complications | 1 | 2019 | 1117 | 0.030 |
Why?
| Clinical Competence | 1 | 2014 | 284 | 0.030 |
Why?
| Intra-Abdominal Fat | 1 | 2010 | 48 | 0.020 |
Why?
| Hypertension | 1 | 2010 | 293 | 0.020 |
Why?
| Motor Activity | 1 | 2010 | 391 | 0.020 |
Why?
|
|
Doukky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|